Effects of the perfluorochemical emulsion FMIQ on the radiation response of EMT6 tumours.
The effects of FMIQ, a perfluorochemical emulsion based on perfluoro-N-methyldecahydroisoquinoline, were examined using BALB/c mice and EMT6 mammary carcinomas. The radiobiological effects of FMIQ were similar to those found previously for Fluosol in the same tumour/host system. Although the perfluorochemical content (20% w/v) and oxygen-carrying capacity of FMIQ are similar to those of Fluosol, the formulation of FMIQ offers some advantages over that of Fluosol. For example, FMIQ has greater stability during storage. FMIQ also is formulated without pluronic F-68 and is based on a perfluorochemical (FMIQ) having a shorter tissue dwell time than the perfluorotripropylamine in Fluosol; it therefore may produce fewer side-effects than Fluosol. The lifetime of the circulating perfluorochemical droplets in BALB/c mice was longer than FMIQ than for Fluosol; this could offer an advantage in fractionated radiotherapy. These findings give reason to expect that FMIQ may prove to be a better emulsion than Fluosol for clinical use as an adjunct to cancer therapy.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510-8040.
S
S
Rockwell
M
M
Kelley
C G
CG
Irvin
D000818:Animals; D003131:Combined Modality Therapy; D005466:Fluorocarbons / Q000627:therapeutic use*; D007546:Isoquinolines / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D005466:Fluorocarbons; D007546:Isoquinolines; D011838:Radiation-Sensitizing Agents; C065081:perfluoro-N-methyldecahydroisoquinoline